PIN
Pinealon is a synthetic tripeptide bioregulator (Glu-Asp-Arg) developed by Professor Khavinson that targets brain tissue and pineal gland function. It promotes neuroprotection and supports cognitive health during aging.
Regulatory status (as of Sept 2026)
Not FDA-approved. Not among the peptides named in the 2026 PCAC actions.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote7 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Pinealon is a compound with only early, small human studies so far. Pinealon is a synthetic tripeptide bioregulator (Glu-Asp-Arg) developed by Professor Khavinson that targets brain tissue and pineal gland function.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Oral, Sublingual |
| Research stage | Phase 1 / early human |
| Dosing | Published research: Russian geroprotection reports: 32 adults aged 41-83 with polymorbidity and organic brain syndrome received… detailsRussian geroprotection reports: 32 adults aged 41-83 with polymorbidity and organic brain syndrome received Pinealon plus Vesugen, dose and route in the full text (Adv Gerontol 2015). A comparative monitoring study of 110 people is also reported (Adv Gerontol 2016). Other data come from DNA-binding biophysics (EDR peptide).Community-reportedCommunity-reported: 10–20 mcg oral, oral, Sublingual |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a three-amino-acid peptide proposed to affect gene activity in cells; its claimed effects have not been shown in controlled studies. Proposed mechanism: a tripeptide (Glu-Asp-Arg) proposed to enter cells and interact with DNA to modulate gene expression; biophysical work showed it can partly penetrate the DNA major groove (Silanteva 2019). Proposed effects on melatonin synthesis, antioxidant defence and neurotransmitter balance have not been demonstrated; the human studies cited are uncontrolled or observational.
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedUsers have reported doses of 10–20 mcg (oral, sublingual). This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
Pinealon (Glu-Asp-Arg, also known as EDR) is a synthetic tripeptide bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson. It specifically targets the central nervous system and pineal gland. Research has shown that Pinealon can modulate melatonin synthesis, enhance antioxidant defenses in neural tissue, and protect neurons from age-related damage.
Glu-Asp-Arg (3 amino acids)
Molecular Weight: 404.4 Da
Molecular Formula: C15H25N5O8
Structure Details: Linear tripeptide consisting of L-glutamic acid, L-aspartic acid, and L-arginine. The compact structure enables direct cellular uptake and nuclear translocation for DNA interaction.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Pinealon | No published PK data found | Oral, Sublingual | Phase 1 / early human |
| Dihexa | Unknown | Oral or intraperitoneal (rodent studies only); no human administration published | Preclinical (animal) |
| FGL (L) | Unknown | Subcutaneous injection | Preclinical (animal) |
| P21 | Unknown | Oral (mice) | Preclinical (animal) |
| PE-22-28 | No published PK data found | Subcutaneous injection, Intranasal | Preclinical (animal) |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Cognitive category. View All Cognitive Peptides
Anti-Aging, Sleep
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.